Report cover image

Chronic Spontaneous Urticaria- Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 80 Pages
SKU # DEL18679394

Description

Chronic Spontaneous Urticaria- Pipeline Insight, 2024



DelveInsight’s, “Chronic Spontaneous Urticaria- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Chronic Spontaneous Urticaria: Understanding

Chronic Spontaneous Urticaria: Overview

Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema. Weals can affect any site on the body and tend to be distributed widely. Chronic urticaria is diagnosed is based on a history lasting over 6 weeks of daily or episodic weals that last less than 24 hours without the presence of physical trigger factors. The international guidelines recommend limiting investigations in most patients with chronic spontaneous urticaria to differential blood count and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Medicines for the treatment of chronic spontaneous urticarial are antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.

""Chronic Spontaneous Urticaria- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Spontaneous Urticaria pipeline landscape is provided which includes the disease overview and Chronic Spontaneous Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Spontaneous Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Spontaneous Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Spontaneous Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Spontaneous Urticaria.
Chronic Spontaneous Urticaria Emerging Drugs Chapters

This segment of the Chronic Spontaneous Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Spontaneous Urticaria Emerging Drugs
  • Dupilumab: Sanofi
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the preregistration developmental stage.
  • Tezepelumab: Amgen
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). The drug is in Preregistration for Asthma treatment; in Phase III for rhinosinusitis; in Phase II clinical studies for the treatment of chronic urticarial and chronic obstructive pulmonary disease. Tezepelumab is being developed in collaboration with AstraZeneca.
  • Barzolvolimab: Celldex Therapeutics
Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.

Further product details are provided in the report……..

Chronic Spontaneous Urticaria: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Spontaneous Urticaria drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Chronic Spontaneous Urticaria
There are approx. 20+ key companies which are developing the therapies for Chronic Spontaneous Urticaria. The companies which have their Chronic Spontaneous Urticaria drug candidates in the most advanced stage, i.e. preregistration, Sanofi.
  • Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal antibody
  • Small molecule
  • Peptide
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Spontaneous Urticaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Spontaneous Urticaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Spontaneous Urticaria drugs.

Chronic Spontaneous Urticaria Report Insights
  • Chronic Spontaneous Urticaria Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Chronic Spontaneous Urticaria Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Chronic Spontaneous Urticaria drugs?
  • How many Chronic Spontaneous Urticaria drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Spontaneous Urticaria?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Spontaneous Urticaria therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Spontaneous Urticaria and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • United BioPharma
  • Teva Pharmaceuticals Development, Inc.
  • Amgen
  • Novartis Pharmaceuticals
  • Allakos Inc.
  • Sanofi
  • Celltrion
  • Celldex Therapeutics
  • MICROBIO GROUP.
  • Escient Pharmaceuticals
  • Jasper Therapeutics
  • Glenmark Pharmaceuticals
  • Taiho Pharmaceuticals
  • ValenzaBio
  • Carna Biosciences
  • Servier
Key Products
  • LOU064
  • Dupilumab
  • Barzolvolimab
  • UB221
  • Lirentelimab
  • CT-P39
  • Tezepelumab
  • TEV-45779
  • FB-31
  • Briquilimab
  • GBR 310
  • TAS5315
  • EP 262
  • Anti-CD40

Table of Contents

80 Pages
Introduction
Executive Summary
Chronic Spontaneous Urticaria: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Spontaneous Urticaria– DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Dupilumab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Comparative Analysis
Remibrutinib: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tezepelumab: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug: Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Briquilimab: Jasper Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Spontaneous Urticaria Key Companies
Chronic Spontaneous Urticaria Key Products
Chronic Spontaneous Urticaria- Unmet Needs
Chronic Spontaneous Urticaria- Market Drivers and Barriers
Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
Chronic Spontaneous Urticaria Analyst Views
Chronic Spontaneous Urticaria Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us